Matinas Biopharma (MTNB) News Today $0.70 +0.03 (+5.11%) As of 05/22/2026 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsOwnershipSEC FilingsShort InterestBuy This Stock MTNB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Matinas Biopharma (NYSEAMERICAN:MTNB) Trading Down 3.7% - Time to Sell?May 19, 2026 | americanbankingnews.comMatinas BioPharma Holdings, Inc.April 8, 2026 | edition.cnn.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsApril 3, 2026 | finance.yahoo.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsApril 3, 2026 | globenewswire.comMatinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203September 24, 2025 | msn.comMTNB Matinas BioPharma Holdings, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comMatinas BioPharma Holdings, Inc. (MTNB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMatinas BioPharma amends bylaws, updates on officer agreementsMay 4, 2025 | investing.comMatinas BioPharma files to sell 16.9M shares of common stock for holdersApril 24, 2025 | markets.businessinsider.comMatinas BioPharma secures shareholder nods on key proposalsApril 6, 2025 | investing.comMatinas BioPharma announces board chairman’s departureMarch 16, 2025 | investing.comMatinas BioPharma appoints Murphy, Neugeboren to board of directorsMarch 11, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsMarch 11, 2025 | finance.yahoo.comMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comMatinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairFebruary 9, 2025 | nasdaq.comMatinas BioPharma appoints Evelyn D’An to board of directorsFebruary 7, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | finance.yahoo.comMatinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | globenewswire.comMatinas BioPharma announces board member resignationJanuary 25, 2025 | msn.com111 Equity Group increases stake in Matinas BioPharmaJanuary 24, 2025 | markets.businessinsider.com111 Equity ups stake in Matinas Biopharma HoldingsJanuary 24, 2025 | msn.com111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.January 24, 2025 | finance.yahoo.comMatinas BioPharma Receives NYSE Noncompliance NoticeJanuary 10, 2025 | globenewswire.comMatinas BioPharma Faces Uncertain Future After Halting MAT2203 DevelopmentNovember 16, 2024 | markets.businessinsider.comMatinas BioPharma downgraded to Neutral from Buy at Alliance Global PartnersNovember 2, 2024 | markets.businessinsider.comMaxim Group Downgrades Matinas BioPharma Holdings (MTNB)November 1, 2024 | msn.comMatinas BioPharma downgraded to Hold from Buy at MaximOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma says MAT2203 partnership negotiations terminatedOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionOctober 31, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition in Matinas BioPharmaOctober 25, 2024 | finance.yahoo.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Insider Trading ActivitySeptember 3, 2024 | benzinga.comMatinas BioPharma enacts reverse stock splitAugust 30, 2024 | uk.investing.comMatinas BioPharma Holdings Inc (6LJ.DU)August 25, 2024 | nz.finance.yahoo.comBuy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug DevelopmentAugust 17, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 15, 2024 | finanznachrichten.deMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024August 14, 2024 | markets.businessinsider.comMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024August 7, 2024 | globenewswire.comMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramJune 24, 2024 | globenewswire.comMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.June 13, 2024 | globenewswire.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | investorplace.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 11, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 10, 2024 | finanznachrichten.de Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTNB Media Mentions By Week MTNB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.000.45▲Average Medical News Sentiment MTNB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼10▲MTNB Articles Average Week Get the Latest News and Ratings for MTNB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Matinas Biopharma and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies INAB News APLT News CVKD News LEXX News GNTA News HOOK News INTI News CTXR News PASG News MDCX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MTNB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
